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Staphylococcus aureus and Staphylococcus epidermidis are notable for their propensity to
form biofilms on implanted medical devices. Staphylococcal biofilm infections are typified
by their recalcitrance to antibiotics and ability to circumvent host immune-mediated clear-
ance, resulting in the establishment of chronic infections that are often recurrent in nature.
Indeed, the immunomodulatory lifestyle of biofilms seemingly shapes the host immune
response to ensure biofilm engraftment and persistence in an immune competent host.
Here, we provide a brief review of the mechanisms whereby S. aureus and S. epidermidis
biofilms manipulate host–pathogen interactions and discuss the concept of microenviron-
ment maintenance in infectious outcomes, as well as speculate how these findings pertain
to the challenges of staphylococcal vaccine development.
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INTRODUCTION
Staphylococcus aureus and Staphylococcus epidermidis are highly
opportunistic pathogens and a major cause of nosocomial and
community-associated infections (1–4). While both staphylo-
coccal species harbor multiple virulence factors, they are also
capable of biofilm formation, which represents a communal vir-
ulence determinant to circumvent immune-mediated clearance
and establish persistent infection (5–8). Most medical device-
associated biofilm infections are caused by S. epidermidis and
S. aureus, and both species can also establish biofilms on native
host surfaces, such as infective endocarditis and osteomyelitis (9–
11). Biofilms are heterogeneous bacterial communities encased
within a self-produced matrix composed of eDNA (12), proteins
(13), and polysaccharides (14), and their composition is often
dependent on environmental factors, such as nutrient availability
and mechanical stress (15). Biofilms represent a spatially diverse
population of cells in terms of gene expression and metabolic
activity, which is thought to arise in response to differences in
nutrient, pH, and oxygen gradients within the structure (5, 16).
Biofilm infections are recalcitrant to antibiotics (17, 18), which
often necessitates removal of the infected device or native tissue
and is associated with significant morbidity and economic impact
(10, 19, 20). Indeed, it has been estimated that approximately $1.8
billion is spent annually in the US for the treatment and clinical
management of orthopedic implant-related infections (21, 22).
Neutrophils and macrophages are the main innate immune
effectors against acute planktonic staphylococcal infections (i.e.,
abscess, sepsis) (23–29). Neutrophil antimicrobial activity is medi-
ated by defensins, cathelicidins, and lysozymes, as well as reactive
oxygen species catalyzed by NADPH oxidase (30, 31). Recently,
neutrophil and macrophage extracellular traps (NETs and METs,
respectively) have been identified as another means of antimicro-
bial action (31–34). This“beyond the grave”mechanism is typified
by an extracellular net of DNA released from dying phagocytes that
contains localized islands of lytic enzymes that kill ensnared extra-
cellular bacteria. Classically activated (M1) macrophages are key
microbicidal effectors that exert their effector functions, in part,
through the production of reactive oxygen and nitrogen species,
in addition to proinflammatory cytokines (35–38). Macrophages
also clear extracellular bacteria by phagocytosis, which is tightly
linked with proinflammatory cytokine and chemokine produc-
tion to initiate adaptive immune responses (39–41). Collectively,
these innate leukocyte responses, coupled with complement acti-
vation, usually ensure the successful clearance of planktonic
staphylococcal infections in an immune competent host.
In contrast, a very different story has emerged regarding biofilm
infections (Figure 1). Recent studies have demonstrated that
staphylococcal biofilms actively skew host immunity toward an
anti-inflammatory, pro-fibrotic response that favors bacterial per-
sistence (6, 42–44). This is typified by alternatively activated (M2)
macrophages and arginase-1 (Arg1) activity, resulting in urea and
ornithine production, which are involved in collagen formation
and tissue remodeling (35, 45, 46). Our laboratory has shown
that macrophages associated with S. aureus biofilms both in vitro
and in vivo have decreased inducible nitric oxide synthase (iNOS)
concomitant with increased Arg1 expression, as well as attenuated
cytokine and chemokine production (6, 43, 44). Similar findings
have been reported in response to S. epidermidis biofilms (42, 47–
49) and biofilms from other bacterial species (50–53), suggesting
a conserved mechanism exists to thwart host immunity to ensure
biofilm persistence (54). However, recent data suggest a protective
role of anti-inflammatory Th2/Treg cells, as opposed to proin-
flammatory Th1/Th17 signaling, during early S. aureus biofilm
development (55), highlighting the complexity of staphylococ-
cal biofilm infections and perhaps distinctions between innate
and adaptive immune mechanisms. For in-depth discussions on
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FIGURE 1 | Game of hide-and-seek between staphylococcal biofilms
and host innate immunity. (1A) Planktonic staphylococci (yellow) are
more readily phagocytosed and cleared by innate immune cells, such as
macrophages (MΦ; blue) and neutrophils (PMNs), triggering a M1
proinflammatory response. (1B) Differential gene expression between
planktonic and biofilm staphylococci provide survival benefits in harsh
environments, such as the presence of an extracellular matrix (green). In
addition, S. aureus biofilms exhibit differential gene expression in response
to macrophages or neutrophils (violet), shielding the biofilm from detection
by the former while facilitating cytotoxicity of the latter. (2A) Staphylococcal
biofilm protein secretion in vivo is relatively unknown and may represent
fertile ground for clinical intervention and/or vaccine development. (2B)
Staphylococcal biofilms are composed of a large biomass, of which some
cells are metabolically active and transform the surrounding
microenvironment by establishing various metabolic gradients. (3A)
Implanted medical devices (gray) not only provide a scaffold for bacterial
adhesion and biofilm formation that is facilitated through host protein
deposition (tan), but can also induce a persistent, anti-inflammatory
immune response that favors bacterial persistence. (3B). Tissue damage
provoked by staphylococcal nutrient procurement may further incite an
overall anti-inflammatory milieu.
host immunity to staphylococcal infections, the reader is referred
to recent reviews (7, 56–58). This Perspective is focused on
how changes in biofilm gene expression/secretion impact host
immune mechanisms and potential implications regarding novel
therapeutic strategies.
DIFFERENTIAL GENE EXPRESSION IN STAPHYLOCOCCAL
BIOFILMS: A GAME OF HIDE-AND-SEEK
Staphylococcal biofilms exhibit distinct gene expression profiles
compared to planktonic cells, demonstrating unique growth dif-
ferences between the two lifestyles (16, 59, 60). One major disparity
in staphylococcal biofilms is the induction of genes associated with
potential acid tolerance response pathways (i.e., arginine deimi-
nase and urease), reflecting anaerobic growth and the need for pH
homeostasis (5, 16). In addition, an increased demand for pyrim-
idine nucleotide biosynthesis has been associated with the biofilm
lifestyle of staphylococci (16) and other bacterial species (61, 62).
The DNA-binding regulatory protein SarA is critical for biofilm
formation and virulence factor expression in both S. aureus and
S. epidermidis. SarA acts, in part, through the accessory gene reg-
ulator agr, which encodes a quorum-sensing system responsible
for transitioning the synthesis of surface and adhesive molecules
to secreted factors and is an important regulatory switch between
planktonic and biofilm lifestyles (63–66).
In addition to unique genetic changes during biofilm growth,
we have recently reported that innate immune cells (i.e.,
macrophages and neutrophils) alter biofilm gene expression pro-
files (67). Transcriptome analysis of S. aureus biofilms following
macrophage exposure revealed a rapid down-regulation of over
550 staphylococcal genes within a 1 h period. This effect occurred
despite the fact that macrophages did not significantly invade the
biofilm or exhibit phagocytic activity. This transcriptional repres-
sion was mitigated after 24 h, which was likely explained by the
significant degree of macrophage death observed at this late inter-
val. In essence, the biofilm was no longer required to cloak itself,
since the threat of macrophage attack had dissipated. In con-
trast, although neutrophils displayed a much higher propensity
for biofilm invasion and phagocytosis, they did not significantly
alter the biofilm transcriptome over similar time periods (67).
This data supports previous reports demonstrating that biofilms
are not inherently protected from neutrophil assault (44, 68, 69).
These results suggest that staphylococcal biofilms “hide” in
response to macrophages while they elect to tackle neutrophil
challenge head on. But why does the biofilm down-regulate gene
expression in the face of a seemingly inactive macrophage chal-
lenge and barely break a transcriptional sweat when confronted
with an assault of phagocytic neutrophils? One possibility involves
the reported ability of S. aureus to survive intracellularly in neu-
trophils (70, 71). Another is that S. aureus secretes a number of
neutrophil-lytic toxins, including α-toxin (Hla) (72) and phenol-
soluble modulins (PSMs) (73–77). Interestingly, both Hla and
PSMs are under agr control, and agr expression was significantly
increased in S. aureus biofilms following neutrophil exposure (67,
74). Notably, we have found few neutrophil infiltrates in either
S. aureus catheter-associated or orthopedic implant models of
biofilm infection in vivo (7, 44). Likewise, the exogenous intro-
duction of neutrophils at the site of S. aureus biofilm infection
is not capable of limiting bacterial growth, whereas M1-activated
macrophages can significantly prevent or clear established biofilms
(44). Collectively, these findings highlight the well-adapted nature
of S. aureus biofilms to neutrophils. Although both neutrophils
and macrophages are phagocytic, macrophages are recognized as
a signaling hub during bacterial infections to coordinate evolv-
ing immune responses through cytokine and chemokine release
(78–80). While it is possible that staphylococcal biofilms are more
responsive to this secreted milieu than physical disruption via
phagocytosis, it is clear that they respond differently to chal-
lenges from distinct leukocyte populations in regards to their
transcriptional profile.
MICROENVIRONMENT MODULATION
Previous work has characterized numerous secreted virulence
factors used by staphylococci that target specific host cell pop-
ulations. S. aureus, in particular, utilizes numerous hemolysins
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(81), leukocidins (82, 83), and proteases to evade the host immune
system (84). While staphylococci certainly divert resources from
secreted to structural proteins during early biofilm growth, pro-
tein secretion is still maintained in biofilms. For example, several
reports have demonstrated that various bacterial biofilm-forming
species secrete peptides and full-length proteins (i.e., Esp) that
interfere with biofilm development of competing organisms, pre-
sumably to eliminate competition for a biofilm-friendly niche
(85–87). Additionally, studies have demonstrated evidence of host-
biofilm cross-talk involving the quorum-sensing molecules N -
Acyl homoserine lactones (AHL) (88, 89). Therefore, it is likely
that staphylococcal biofilms also secrete factors in vivo, perhaps
under quorum-sensing system regulation, in an attempt to evade
immune recognition and clearance. However, the identity of such
molecules remains to be elucidated but could represent future
attractive anti-biofilm agents.
Besides virulence factors, staphylococci also secrete mole-
cules for nutrient procurement and cell signaling. For example,
siderophores are critical for iron acquisition (90), while several
signaling molecules are important for biofilm remodeling and
dispersal, such as auto-inducing peptide (AIP) (63), nuclease
(91), and PSMs (74). While the primary roles of these mole-
cules are apparently unrelated to immune interactions, recent
evidence suggests the potential for alternative functions. For exam-
ple, nuclease, which mediates biofilm dispersal (65, 91), can also
participate in NET degradation (32). Recently, nuclease in com-
bination with adenosine synthase has been implicated in the
conversion of NETs to leukotoxic deoxyadenosine, highlighting
a clever means whereby S. aureus turns the immune response
against itself (92). In addition, S. aureus PSM expression is induced
following neutrophil phagocytosis, resulting in neutrophil lysis
and bacterial escape (74, 76, 93). This process is regulated by the
stringent response characterized by the synthesis of the intracel-
lular signaling alarmone (p)ppGpp (93). Therefore, the stringent
response provides yet another means of staphylococcal adaptation
in response to select immune pressures, something that has pre-
viously been well-established in relation to nutrient availability
and metabolism (94–99). Indeed, recent evidence has implicated
(p)ppGpp and di-cyclic NTPs as critical signals in the switch from
planktonic to biofilm growth (100).
However, secreted factors are not the only means whereby
staphylococcal biofilms could regulate the host response in an
exogenous manner. While bacteria have a plethora of environmen-
tal sensory mechanisms at their disposal, host immune cells are
also very sensitive to their surrounding environment (101–103).
Because biofilms represent a large biomass, the sum metabolic
activity of the bacteria themselves would be expected to have
an impact on pH and oxygen levels in the surrounding tissue
microenvironment. Indeed, even subtle changes in pH (101, 104)
or oxygen (102) can significantly alter the nature of the immune
response. Furthermore, novel research with fungal and bacterial
biofilms has identified a coordinated system of ROS signaling for
biofilm maturation (105). It will be interesting to see what, if
any, impact this biofilm ROS gradient has on the host immune
response and whether host-generated ROS can also act as a signal-
ing molecule within the biofilm to influence target pathways, such
as biofilm formation via quorum-sensing (105).
HIJACKING THE HOST RESPONSE
Most implanted medical devices are at risk for biofilm coloniza-
tion (4, 10, 11, 15). Upon placement, the device is conditioned by
host proteins, such as fibronectin and collagen, which can serve as
ligands for bacterial attachment via microbial surface components
recognizing adhesive matrix molecules (MSCRAMMS) (4, 9, 11,
15, 106, 107). Therefore, the wound healing responses elicited after
medical device implantation can inadvertently provide a rich envi-
ronment for bacterial colonization; however, they can also set the
stage for a very specific immune response that is incapable of medi-
ating bacterial clearance, as described below (108). Staphylococcal
biofilm-associated protein (Bap) can facilitate adherence to host
epithelial cells through the inhibition of MSCRAMM-mediated
attachment (109, 110). Following adherence, bacteria begin to pro-
liferate and accumulate by producing adherence factors and matrix
components, resulting in biofilm formation. Bacterial-derived
accumulation-associated protein (Aap) and polysaccharide inter-
cellular adhesin (PIA) are important accumulation molecules in
S. epidermidis.
Our laboratory has reported that S. aureus biofilms promote
their growth and expansion by manipulating the host immune
response (6, 43, 44, 111). Several studies demonstrated that staphy-
lococci have developed strategies to interfere with M1 macrophage
polarization either by directly inhibiting antimicrobial activity
or hindering M1 cytokine production (6, 42, 44, 48). In addi-
tion, the expression of numerous proinflammatory mediators is
significantly attenuated during S. aureus biofilm infection (6, 7,
43, 44). Since many of these molecules are also associated with
wound healing responses, their active repression by staphylococ-
cal biofilms is likely one mechanism to explain the paucity of
neutrophil and M1-activated macrophage infiltrates into biofilms
in vivo (6, 43, 44).
Besides dampening the local inflammatory environment,
numerous mechanisms likely exist to explain the chronicity of
staphylococcal biofilm infections in an immune competent host.
For example, we have demonstrated the preferential accumulation
of M2-activated macrophages in S. aureus biofilms in vivo and
in vitro typified by Arg1 concomitant with minimal iNOS expres-
sion (6, 43, 44). Increased Arg1 activity during staphylococcal
infection can regulate T cell proliferation and effector functions
via arginine depletion from the environment, resulting in defective
TCR signaling from inhibiting CD3ζ expression, cell cycle, and
cytokine production (112–116). Indeed, our laboratory has found
few T cell infiltrates associated with S. aureus biofilm infections,
whereas another group reported Th2/Treg involvement in biofilm
clearance (7, 55). The reasons for these discrepancies are not clear
but may arise from differences in experimental models and/or
S. aureus strains tested. Impaired adaptive immunity or mem-
ory responses could compromise the success of vaccine strategies
against staphylococcal biofilms.
FUTURE DIRECTIONS
As ongoing staphylococcal biofilm research elucidates mecha-
nisms contributing to the persistence and virulence of these
infections, it is becoming clear that novel strategies are needed
to combat the complex biofilm lifestyle. The inherent abil-
ity of S. aureus to circumvent immune-mediated clearance has
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complicated staphylococcal vaccine development. Indeed, pre-
vious studies have shown that S. aureus infection alone is not
sufficient to induce protective immunity (117). Moreover, recent
vaccine development efforts have stalled in clinical trials, likely
due to the organism’s immunomodulatory capabilities coupled
with the differential expression of targeted antigens in vivo (118–
120). Another challenge is to develop a vaccine efficacious against
both planktonic and biofilm infections that provides protection
across a wide range of S. aureus clonal complex groups (121).
Recent staphylococcal vaccine efforts have utilized new
approaches to increase efficacy. Vaccination with attenuated S.
aureus strains (122) has led to the discovery of protective antigens
with vaccine potential in a process termed “genetic vaccinology”
(123, 124). In addition, multivalent vaccines targeting multiple
secreted and cell surface-associated virulence factors from both
planktonic (125), and biofilm (126, 127) modes of growth have
been employed with some success in vivo (121, 128). Further-
more, the use of Toll-like receptor agonists as adjuvants and novel
DNA vaccines are currently under investigation (129, 130). While
the efforts of our laboratory and others have implicated a sub-
set of putative factors responsible for the immunosuppressive
and chronic nature of staphylococcal biofilms, significant obsta-
cles remain for developing a successful vaccine. In our opinion,
future anti-staphylococcal therapeutics for the biofilm lifestyle
will likely require a combinatorial approach of bacteriocidal and
immunostimulatory treatments.
In this context, a successful staphylococcal vaccine may be facil-
itated by a more comprehensive understanding of the staphylococ-
cal biofilm transcriptome and secretome, particularly in response
to relevant host phagocytes, which will be an important next
step toward replicating complex in vivo interactions. Additional
insights into staphylococcal biofilm metabolism, in particular, how
the biofilm metabolome changes once immune cells are encoun-
tered, may be beneficial as it could facilitate the identification of
virulence determinants for vaccine development. A recent analogy
is the use of metabolic stimuli to induce aminoglycoside suscepti-
bility in otherwise recalcitrant S. aureus cell populations, such as
biofilms (131). Also, characterizing how the natural wound healing
response promotes bacterial colonization could provide invaluable
information on key immune cell populations for vaccine target-
ing. A better understanding of how biofilms manipulate the host
immune response should provide valuable insights to direct the
continued evolution of staphylococcal vaccines. Until, we better
define how staphylococci circumvent host immunity, they will
likely continue to have the upper hand.
ACKNOWLEDGMENTS
This work was supported by the National Institute of Allergy and
Infectious Diseases (NIAID) P01 AI083211 to Tammy Kielian and
an American Heart Association predoctoral fellowship to Cortney
E. Heim (13PRE16910040).
REFERENCES
1. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant
microorganisms. Clin Microbiol Rev (2002) 15:167–93. doi:10.1128/CMR.15.
2.167-193.2002
2. Fitzpatrick F, Humphreys H, O’Gara JP. The genetics of staphylococcal
biofilm formation – will a greater understanding of pathogenesis lead to
better management of device-related infection? Clin Microbiol Infect (2005)
11:967–73. doi:10.1111/j.1469-0691.2005.01274.x
3. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol (2008)
322:207–28. doi:10.1007/978-3-540-75418-3_10
4. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm
formation in Staphylococcus implant infections. A review of molecular mech-
anisms and implications for biofilm-resistant materials. Biomaterials (2012)
33:5967–82. doi:10.1016/j.biomaterials.2012.05.031
5. Fey PD, Olson ME. Current concepts in biofilm formation of Staphylococcus
epidermidis. Future Microbiol (2010) 5:917–33. doi:10.2217/fmb.10.56
6. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, et al.
Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate
inflammation in vivo. J Immunol (2011) 186:6585–96. doi:10.4049/jimmunol.
1002794
7. Hanke ML, Kielian T. Deciphering mechanisms of staphylococcal biofilm eva-
sion of host immunity. Front Cell Infect Microbiol (2012) 2:62. doi:10.3389/
fcimb.2012.00062
8. Watkins RR, David MZ, Salata RA. Current concepts on the virulence mech-
anisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol (2012)
61:1179–93. doi:10.1099/jmm.0.043513-0
9. McCann MT, Gilmore BF, Gorman SP. Staphylococcus epidermidis device-
related infections: pathogenesis and clinical management. J Pharm Pharmacol
(2008) 60:1551–71. doi:10.1211/jpp/60.12.0001
10. Montanaro L, Speziale P, Campoccia D, Ravaioli S, Cangini I, Pietrocola G, et al.
Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol
(2011) 6:1329–49. doi:10.2217/fmb.11.117
11. Otto M. Staphylococcal infections: mechanisms of biofilm maturation and
detachment as critical determinants of pathogenicity. Annu Rev Med (2013)
64:175–88. doi:10.1146/annurev-med-042711-140023
12. Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, et al. The cidA
murein hydrolase regulator contributes to DNA release and biofilm develop-
ment in Staphylococcus aureus. Proc Natl Acad Sci U S A (2007) 104:8113–8.
doi:10.1073/pnas.0610226104
13. Schwartz K, Syed AK, Stephenson RE, Rickard AH, Boles BR. Functional amy-
loids composed of phenol soluble modulins stabilize Staphylococcus aureus
biofilms. PLoS Pathog (2012) 8:e1002744. doi:10.1371/journal.ppat.1002744
14. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, et al.
Polysaccharide intercellular adhesin or protein factors in biofilm accumula-
tion of Staphylococcus epidermidis and Staphylococcus aureus isolated from
prosthetic hip and knee joint infections. Biomaterials (2007) 28:1711–20.
doi:10.1016/j.biomaterials.2006.11.046
15. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal
biofilm infections. Ann N Y Acad Sci (2011) 1241:104–21. doi:10.1111/j.1749-
6632.2011.06281.x
16. Beenken KE, Dunman PM, Mcaleese F, Macapagal D, Murphy E, Projan SJ, et al.
Global gene expression in Staphylococcus aureus biofilms. J Bacteriol (2004)
186:4665–84. doi:10.1128/JB.186.14.4665-4684.2004
17. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm
device: new technology for rapid determination of antibiotic susceptibilities of
bacterial biofilms. J Clin Microbiol (1999) 37:1771–6.
18. Anderl JN, Zahller J, Roe F, Stewart PS. Role of nutrient limitation and
stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampi-
cillin and ciprofloxacin. Antimicrob Agents Chemother (2003) 47:1251–6.
doi:10.1128/AAC.47.4.1251-1256.2003
19. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med
(2004) 351:1645–54. doi:10.1056/NEJMra040181
20. Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sanchez-Somolinos M,
Baraia-Etxaburu JM, et al. A large multicenter study of methicillin-susceptible
and methicillin-resistant Staphylococcus aureus prosthetic joint infections man-
aged with implant retention. Clin Infect Dis (2013) 56:182–94. doi:10.1093/cid/
cis746
21. Darouiche RO. Treatment of infections associated with surgical implants.
N Engl J Med (2004) 350:1422–9. doi:10.1056/NEJMra035415
22. Haenle M, Skripitz C, Mittelmeier W, Skripitz R. Economic impact of
infected total knee arthroplasty. ScientificWorldJournal (2012) 2012:196515.
doi:10.1100/2012/196515
23. Verdrengh M, Tarkowski A. Role of neutrophils in experimental septicemia
and septic arthritis induced by Staphylococcus aureus. Infect Immun (1997)
65:2517–21.

























































Scherr et al. Biofilm modulation of host immunity
24. Molne L, Verdrengh M, Tarkowski A. Role of neutrophil leukocytes in
cutaneous infection caused by Staphylococcus aureus. Infect Immun (2000)
68:6162–7. doi:10.1128/IAI.68.11.6162-6167.2000
25. Verdrengh M, Tarkowski A. Role of macrophages in Staphylococcus aureus-
induced arthritis and sepsis. Arthritis Rheum (2000) 43:2276–82. doi:10.1002/
1529-0131(200010)43:10<2276::AID-ANR15>3.0.CO;2-C
26. Kielian T, Barry B, Hickey WF. CXC chemokine receptor-2 ligands are
required for neutrophil-mediated host defense in experimental brain abscesses.
J Immunol (2001) 166:4634–43.
27. Asai A, Tsuda Y, Kobayashi M, Hanafusa T, Herndon DN, Suzuki F. Pathogenic
role of macrophages in intradermal infection of methicillin-resistant Staphy-
lococcus aureus in thermally injured mice. Infect Immun (2010) 78:4311–9.
doi:10.1128/IAI.00642-10
28. Cheng AG, Dedent AC, Schneewind O, Missiakas D. A play in four acts:
Staphylococcus aureus abscess formation. Trends Microbiol (2011) 19:225–32.
doi:10.1016/j.tim.2011.01.007
29. Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylo-
coccus aureus infections. Semin Immunopathol (2012) 34:237–59. doi:10.1007/
s00281-011-0295-3
30. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev
Immunol (2006) 6:173–82. doi:10.1038/nri1785
31. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated
view. Immunol Rev (2007) 219:88–102. doi:10.1111/j.1600-065X.2007.00550.x
32. Berends ET, Horswill AR, Haste NM, Monestier M, Nizet V, Von Kockritz-
Blickwede M. Nuclease expression by Staphylococcus aureus facilitates escape
from neutrophil extracellular traps. J Innate Immun (2010) 2:576–86. doi:10.
1159/000319909
33. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the
second function of chromatin? J Cell Biol (2012) 198:773–83. doi:10.1083/jcb.
201203170
34. Goldmann O, Medina E. The expanding world of extracellular traps: not only
neutrophils but much more. Front Immunol (2012) 3:420. doi:10.3389/fimmu.
2012.00420
35. Mosser DM. The many faces of macrophage activation. J Leukoc Biol (2003)
73:209–12. doi:10.1189/jlb.0602325
36. Martinez FO. Regulators of macrophage activation. Eur J Immunol (2011)
41:1531–4. doi:10.1002/eji.201141670
37. Mege JL, Mehraj V, Capo C. Macrophage polarization and bacterial infections.
Curr Opin Infect Dis (2011) 24:230–4. doi:10.1097/QCO.0b013e328344b73e
38. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation.
Nat Rev Immunol (2011) 11:762–74. doi:10.1038/nri3070
39. Aderem A. Phagocytosis and the inflammatory response. J Infect Dis (2003)
187(Suppl 2):S340–5. doi:10.1086/374747
40. Underhill DM, Gantner B. Integration of Toll-like receptor and phagocytic sig-
naling for tailored immunity. Microbes Infect (2004) 6:1368–73. doi:10.1016/j.
micinf.2004.08.016
41. Underhill DM, Goodridge HS. Information processing during phagocytosis.
Nat Rev Immunol (2012) 12:492–502. doi:10.1038/nri3244
42. Schommer NN, Christner M, Hentschke M, Ruckdeschel K, Aepfelbacher M,
Rohde H. Staphylococcus epidermidis uses distinct mechanisms of biofilm
formation to interfere with phagocytosis and activation of mouse
macrophage-like cells 774A.1. Infect Immun (2011) 79:2267–76. doi:10.1128/
IAI.01142-10
43. Hanke ML, Angle A, Kielian T. MyD88-dependent signaling influences fibrosis
and alternative macrophage activation during Staphylococcus aureus biofilm
infection. PLoS One (2012) 7:e42476. doi:10.1371/journal.pone.0042476
44. Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T. Targeting macrophage
activation for the prevention and treatment of Staphylococcus aureus biofilm
infections. J Immunol (2013) 190:2159–68. doi:10.4049/jimmunol.1202348
45. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation.
Nat Rev Immunol (2008) 8:958–69. doi:10.1038/nri2448
46. Comalada M, Yeramian A, Modolell M, Lloberas J, Celada A. Arginine and
macrophage activation. Methods Mol Biol (2012) 844:223–35. doi:10.1007/978-
1-61779-527-5_16
47. Kristian SA, Birkenstock TA, Sauder U, Mack D, Gotz F, Landmann R. Biofilm
formation induces C3a release and protects Staphylococcus epidermidis from
IgG and complement deposition and from neutrophil-dependent killing.
J Infect Dis (2008) 197:1028–35. doi:10.1086/528992
48. Cerca F,Andrade F, Franca A,Andrade EB, Ribeiro A,Almeida AA, et al. Staphy-
lococcus epidermidis biofilms with higher proportions of dormant bacteria
induce a lower activation of murine macrophages. J Med Microbiol (2011)
60:1717–24. doi:10.1099/jmm.0.031922-0
49. Spiliopoulou AI, Kolonitsiou F, Krevvata MI, Leontsinidis M, Wilkinson TS,
Mack D, et al. Bacterial adhesion, intracellular survival and cytokine induc-
tion upon stimulation of mononuclear cells with planktonic or biofilm
phase Staphylococcus epidermidis. FEMS Microbiol Lett (2012) 330:56–65.
doi:10.1111/j.1574-6968.2012.02533.x
50. Yu H, Head NE. Persistent infections and immunity in cystic fibrosis. Front
Biosci (2002) 7:d442–57.
51. Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB, et al.
Compromised host defense on Pseudomonas aeruginosa biofilms: charac-
terization of neutrophil and biofilm interactions. J Immunol (2003) 171:
4329–39.
52. Mittal R, Sharma S, Chhibber S, Harjai K. Effect of macrophage secretory
products on elaboration of virulence factors by planktonic and biofilm cells of
Pseudomonas aeruginosa. Comp Immunol Microbiol Infect Dis (2006) 29:12–26.
doi:10.1016/j.cimid.2005.11.002
53. Chandra J, Mccormick TS, Imamura Y, Mukherjee PK, Ghannoum MA. Inter-
action of Candida albicans with adherent human peripheral blood mononu-
clear cells increases C. albicans biofilm formation and results in differential
expression of pro- and anti-inflammatory cytokines. Infect Immun (2007)
75:2612–20. doi:10.1128/IAI.01841-06
54. Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr
Top Microbiol Immunol (2006) 306:251–8. doi:10.1007/3-540-29916-5_10
55. Prabhakara R, Harro JM, Leid JG, Keegan AD, Prior ML, Shirtliff ME. Sup-
pression of the inflammatory immune response prevents the development of
chronic biofilm infection due to methicillin-resistant Staphylococcus aureus.
Infect Immun (2011) 79:5010–8. doi:10.1128/IAI.05571-11
56. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus
aureus infections. Infect Dis Clin North Am (2009) 23:17–34. doi:10.1016/j.idc.
2008.10.003
57. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME.
Staphylococcus aureus biofilms: properties, regulation, and roles in human dis-
ease. Virulence (2011) 2:445–59. doi:10.4161/viru.2.5.17724
58. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections
and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol
(2012) 15:92–9. doi:10.1016/j.mib.2011.10.012
59. Resch A, Rosenstein R, Nerz C, Gotz F. Differential gene expression profiling
of Staphylococcus aureus cultivated under biofilm and planktonic conditions.
Appl Environ Microbiol (2005) 71:2663–76. doi:10.1128/AEM.71.5.2663-2676.
2005
60. Yao Y, Sturdevant DE, Otto M. Genomewide analysis of gene expression in
Staphylococcus epidermidis biofilms: insights into the pathophysiology of S.
epidermidis biofilms and the role of phenol-soluble modulins in formation of
biofilms. J Infect Dis (2005) 191:289–98. doi:10.1086/426945
61. Garavaglia M, Rossi E, Landini P. The pyrimidine nucleotide biosynthetic path-
way modulates production of biofilm determinants in Escherichia coli. PLoS
One (2012) 7:e31252. doi:10.1371/journal.pone.0031252
62. Yadav MK, Kwon SK, Cho CG, Park SW, Chae SW, Song JJ. Gene expression pro-
file of early in vitro biofilms of Streptococcus pneumoniae. Microbiol Immunol
(2012) 56:621–9. doi:10.1111/j.1348-0421.2012.00483.x
63. Ji G, Beavis RC, Novick RP. Cell density control of staphylococcal virulence
mediated by an octapeptide pheromone. Proc Natl Acad Sci U S A (1995)
92:12055–9. doi:10.1073/pnas.92.26.12055
64. Beenken KE, Blevins JS, Smeltzer MS. Mutation of sarA in Staphylococcus aureus
limits biofilm formation. Infect Immun (2003) 71:4206–11. doi:10.1128/IAI.71.
7.4206-4211.2003
65. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus
biofilms. PLoS Pathog (2008) 4:e1000052. doi:10.1371/journal.ppat.1000052
66. Mrak LN, Zielinska AK, Beenken KE, Mrak IN, Atwood DN, Griffin LM, et al.
saeRS and sarA act synergistically to repress protease production and pro-
mote biofilm formation in Staphylococcus aureus. PLoS One (2012) 7:e38453.
doi:10.1371/journal.pone.0038453
67. Scherr TD, Roux CM, Hanke ML, Angle A, Dunman PD, Kielian T. Global
transcriptome analysis of Staphylococcus aureus biofilms in response to innate
immune cells. Infect Immun (2013) 81:4363–76. doi:10.1128/IAI.00819-13

























































Scherr et al. Biofilm modulation of host immunity
68. Gunther F, Wabnitz GH, Stroh P, Prior B, Obst U, Samstag Y, et al. Host defence
against Staphylococcus aureus biofilms infection: phagocytosis of biofilms by
polymorphonuclear neutrophils (PMN). Mol Immunol (2009) 46:1805–13.
doi:10.1016/j.molimm.2009.01.020
69. Graves SF, Kobayashi SD, Deleo FR. Community-associated methicillin-
resistant Staphylococcus aureus immune evasion and virulence. J Mol Med (Berl)
(2010) 88:109–14. doi:10.1007/s00109-009-0573-x
70. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP.
Survival of Staphylococcus aureus inside neutrophils contributes to infection. J
Immunol (2000) 164:3713–22.
71. Anwar S, Prince LR, Foster SJ, Whyte MK, Sabroe I. The rise and rise of Staphy-
lococcus aureus: laughing in the face of granulocytes. Clin Exp Immunol (2009)
157:216–24. doi:10.1111/j.1365-2249.2009.03950.x
72. Spaan AN, Surewaard BG, Nijland R, Van Strijp JA. Neutrophils versus Staphy-
lococcus aureus: a biological tug of war. Annu Rev Microbiol (2013) 67:629–50.
doi:10.1146/annurev-micro-092412-155746
73. Clarke SR. Phenol-soluble modulins of Staphylococcus aureus lure neutrophils
into battle. Cell Host Microbe (2010) 7:423–4. doi:10.1016/j.chom.2010.05.015
74. Periasamy S, Joo HS, Duong AC, Bach TH, Tan VY, Chatterjee SS, et al. How
Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl
Acad Sci U S A (2012) 109:1281–6. doi:10.1073/pnas.1115006109
75. Chatterjee SS, Joo HS, Duong AC, Dieringer TD, Tan VY, Song Y, et al. Essen-
tial Staphylococcus aureus toxin export system. Nat Med (2013) 19:364–7.
doi:10.1038/nm.3047
76. Chatterjee SS, Otto M. How can Staphylococcus aureus phenol-soluble mod-
ulins be targeted to inhibit infection? Future Microbiol (2013) 8:693–6.
doi:10.2217/fmb.13.37
77. Tsompanidou E, Denham EL, Van Dijl JM. Phenol-soluble modulins, hell-
hounds from the staphylococcal virulence-factor pandemonium. Trends Micro-
biol (2013) 21:313–5. doi:10.1016/j.tim.2013.04.007
78. Silva MT. When two is better than one: macrophages and neutrophils work
in concert in innate immunity as complementary and cooperative partners of
a myeloid phagocyte system. J Leukoc Biol (2010) 87:93–106. doi:10.1189/jlb.
0809549
79. Silva MT. Macrophage phagocytosis of neutrophils at inflammatory/infectious
foci: a cooperative mechanism in the control of infection and infectious inflam-
mation. J Leukoc Biol (2011) 89:675–83. doi:10.1189/jlb.0910536
80. Silva MT, Correia-Neves M. Neutrophils and macrophages: the main partners
of phagocyte cell systems. Front Immunol (2012) 3:174. doi:10.3389/fimmu.
2012.00174
81. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD, et al.
Staphylococcus aureus alpha-hemolysin mediates virulence in a murine model
of severe pneumonia through activation of the NLRP3 inflammasome. J Infect
Dis (2012) 205:807–17. doi:10.1093/infdis/jir846
82. Dumont AL,Nygaard TK,Watkins RL,Smith A,Kozhaya L,Kreiswirth BN,et al.
Characterization of a new cytotoxin that contributes to Staphylococcus aureus
pathogenesis. Mol Microbiol (2011) 79:814–25. doi:10.1111/j.1365-2958.2010.
07490.x
83. Alonzo F III, Torres VJ. Bacterial survival amidst an immune onslaught: the
contribution of the Staphylococcus aureus leukotoxins. PLoS Pathog (2013)
9:e1003143. doi:10.1371/journal.ppat.1003143
84. Oogai Y, Matsuo M, Hashimoto M, Kato F, Sugai M, Komatsuzawa H. Expres-
sion of virulence factors by Staphylococcus aureus grown in serum. Appl Environ
Microbiol (2011) 77:8097–105. doi:10.1128/AEM.05316-11
85. Otto M, Echner H, Voelter W, Gotz F. Pheromone cross-inhibition between
Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun (2001)
69:1957–60. doi:10.1128/IAI.69.3.1957-1960.2001
86. Qazi S, Middleton B, Muharram SH, Cockayne A, Hill P, O’Shea P, et al. N-
acylhomoserine lactones antagonize virulence gene expression and quorum
sensing in Staphylococcus aureus. Infect Immun (2006) 74:910–9. doi:10.1128/
IAI.74.2.910-919.2006
87. Qin Z, Yang L, Qu D, Molin S, Tolker-Nielsen T. Pseudomonas aerugi-
nosa extracellular products inhibit staphylococcal growth, and disrupt estab-
lished biofilms produced by Staphylococcus epidermidis. Microbiology (2009)
155:2148–56. doi:10.1099/mic.0.028001-0
88. Williams P. Quorum sensing, communication and cross-kingdom signalling
in the bacterial world. Microbiology (2007) 153:3923–38. doi:10.1099/mic.0.
2007/012856-0
89. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between
bacteria and their hosts. Nat Rev Microbiol (2008) 6:111–20. doi:10.1038/
nrmicro1836
90. Friedman DB, Stauff DL, Pishchany G, Whitwell CW, Torres VJ, Skaar EP.
Staphylococcus aureus redirects central metabolism to increase iron availability.
PLoS Pathog (2006) 2:e87. doi:10.1371/journal.ppat.0020087
91. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, et al. Mod-
ulation of eDNA release and degradation affects Staphylococcus aureus biofilm
maturation. PLoS One (2009) 4:e5822. doi:10.1371/journal.pone.0005822
92. Thammavongsa V, Missiakas DM, Schneewind O. Staphylococcus aureus
degrades neutrophil extracellular traps to promote immune cell death. Science
(2013) 342:863–6. doi:10.1126/science.1242255
93. Geiger T, Francois P, Liebeke M, Fraunholz M, Goerke C, Krismer B, et al. The
stringent response of Staphylococcus aureus and its impact on survival after
phagocytosis through the induction of intracellular PSMs expression. PLoS
Pathog (2012) 8:e1003016. doi:10.1371/journal.ppat.1003016
94. Novick RP. Autoinduction and signal transduction in the regulation of staphy-
lococcal virulence. Mol Microbiol (2003) 48:1429–49. doi:10.1046/j.1365-2958.
2003.03526.x
95. Somerville GA, Said-Salim B, Wickman JM, Raffel SJ, Kreiswirth BN, Musser
JM. Correlation of acetate catabolism and growth yield in Staphylococcus
aureus: implications for host-pathogen interactions. Infect Immun (2003)
71:4724–32. doi:10.1128/IAI.71.8.4724-4732.2003
96. Seidl K, Goerke C, Wolz C, Mack D, Berger-Bachi B, Bischoff M. Staphylococ-
cus aureus CcpA affects biofilm formation. Infect Immun (2008) 76:2044–50.
doi:10.1128/IAI.00035-08
97. Somerville GA, Proctor RA. At the crossroads of bacterial metabolism and viru-
lence factor synthesis in Staphylococci. Microbiol Mol Biol Rev (2009) 73:233–48.
doi:10.1128/MMBR.00005-09
98. Sadykov MR, Zhang B, Halouska S, Nelson JL, Kreimer LW, Zhu Y, et al. Using
NMR metabolomics to investigate tricarboxylic acid cycle-dependent signal
transduction in Staphylococcus epidermidis. J Biol Chem (2010) 285:36616–24.
doi:10.1074/jbc.M110.152843
99. Nuxoll AS, Halouska SM, Sadykov MR, Hanke ML, Bayles KW, Kielian T,
et al. CcpA regulates arginine biosynthesis in Staphylococcus aureus through
repression of proline catabolism. PLoS Pathog (2012) 8:e1003033. doi:10.1371/
journal.ppat.1003033
100. Valle J, Solano C, Garcia B, Toledo-Arana A, Lasa I. Biofilm switch and immune
response determinants at early stages of infection. Trends Microbiol (2013)
21:364–71. doi:10.1016/j.tim.2013.05.008
101. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol
(2001) 69:522–30.
102. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune
responses. Nat Rev Immunol (2009) 9:609–17. doi:10.1038/nri2607
103. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3
inflammasome. Immunol Rev (2011) 243:152–62. doi:10.1111/j.1600-065X.
2011.01043.x
104. Rajamaki K, Nordstrom T, Nurmi K, Akerman KE, Kovanen PT, Oorni K, et al.
Extracellular acidosis is a novel danger signal alerting innate immunity via
the NLRP3 inflammasome. J Biol Chem (2013) 288:13410–9. doi:10.1074/jbc.
M112.426254
105. Cap M,Vachova L, Palkova Z. Reactive oxygen species in the signaling and adap-
tation of multicellular microbial communities. Oxid Med Cell Longev (2012)
2012:976753. doi:10.1155/2012/976753
106. Joh D, Wann ER, Kreikemeyer B, Speziale P, Hook M. Role of fibronectin-
binding MSCRAMMs in bacterial adherence and entry into mammalian cells.
Matrix Biol (1999) 18:211–23. doi:10.1016/S0945-053X(99)00025-6
107. Fowler T, Wann ER, Joh D, Johansson S, Foster TJ, Hook M. Cellular invasion
by Staphylococcus aureus involves a fibronectin bridge between the bacterial
fibronectin-binding MSCRAMMs and host cell beta1 integrins. Eur J Cell Biol
(2000) 79:672–9. doi:10.1078/0171-9335-00104
108. Rochford ET, Richards RG, Moriarty TF. Influence of material on the develop-
ment of device-associated infections. Clin Microbiol Infect (2012) 18:1162–7.
doi:10.1111/j.1469-0691.2012.04002.x
109. Cucarella C, Tormo MA, Knecht E, Amorena B, Lasa I, Foster TJ, et al. Expres-
sion of the biofilm-associated protein interferes with host protein receptors
of Staphylococcus aureus and alters the infective process. Infect Immun (2002)
70:3180–6. doi:10.1128/IAI.70.6.3180-3186.2002

























































Scherr et al. Biofilm modulation of host immunity
110. Valle J, Latasa C, Gil C, Toledo-Arana A, Solano C, Penades JR, et al.
Bap, a biofilm matrix protein of Staphylococcus aureus prevents cellular
internalization through binding to GP96 host receptor. PLoS Pathog (2012)
8:e1002843. doi:10.1371/journal.ppat.1002843
111. Cheatle J, Aldrich A, Thorell WE, Boska MD, Kielian T. Compartmentalization
of immune responses during Staphylococcus aureus cranial bone flap infection.
Am J Pathol (2013) 183:450–8. doi:10.1016/j.ajpath.2013.04.031
112. Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park HJ, Lan MS, et al. l-Arginine
regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat
cells. Clin Cancer Res (2001) 7:958s–65s.
113. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. l-arginine metabo-
lism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003)
24:302–6. doi:10.1016/S1471-4906(03)00132-7
114. Rodriguez PC, Zea AH, Desalvo J, Culotta KS, Zabaleta J, Quiceno DG, et al. l-
arginine consumption by macrophages modulates the expression of CD3 zeta
chain in T lymphocytes. J Immunol (2003) 171:1232–9.
115. Popovic PJ, Zeh HJ III, Ochoa JB. Arginine and immunity. J Nutr (2007)
137:1681S–6S.
116. Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-
lymphocyte cell-cycle progression. Blood (2007) 109:1568–73. doi:10.1182/
blood-2006-06-031856
117. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin
Infect Dis (2012) 54:560–7. doi:10.1093/cid/cir828
118. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylo-
coccus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 2:16.
doi:10.3389/fcimb.2012.00016
119. Botelho-Nevers E, Verhoeven P, Paul S, Grattard F, Pozzetto B, Berthelot P,
et al. Staphylococcal vaccine development: review of past failures and plea
for a future evaluation of vaccine efficacy not only on staphylococcal infec-
tions but also on mucosal carriage. Expert Rev Vaccines (2013) 12:1249–59.
doi:10.1586/14760584.2013.840091
120. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: “Staphyloc-
cocus aureus vaccines: problems and prospects”. Vaccine (2013) 31:2723–30.
doi:10.1016/j.vaccine.2013.04.002
121. Harro JM, Peters BM, O’May GA, Archer N, Kerns P, Prabhakara R, et al.
Vaccine development in Staphylococcus aureus: taking the biofilm pheno-
type into consideration. FEMS Immunol Med Microbiol (2010) 59:306–23.
doi:10.1111/j.1574-695X.2010.00708.x
122. Kim HK, Kim HY, Schneewind O, Missiakas D. Identifying protective antigens
of Staphylococcus aureus, a pathogen that suppresses host immune responses.
FASEB J (2011) 25:3605–12. doi:10.1096/fj.11-187963
123. Kim HK, Emolo C, Dedent AC, Falugi F, Missiakas DM, Schneewind O.
Protein A-specific monoclonal antibodies and prevention of Staphylococcus
aureus disease in mice. Infect Immun (2012) 80:3460–70. doi:10.1128/IAI.
00230-12
124. Kim HK, Emolo C, Missiakas D, Schneewind O. A monoclonal antibody that
recognizes the E domain of staphylococcal protein A. Vaccine (2014) 32:464–9.
doi:10.1016/j.vaccine.2013.11.054
125. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface pro-
teins of Staphylococcus aureus. Proc Natl Acad Sci U S A (2006) 103:16942–7.
doi:10.1073/pnas.0606863103
126. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. Vaccination
with clumping factor A and fibronectin binding protein A to prevent Staphylo-
coccus aureus infection of an aortic patch in mice. J Infect Dis (2008) 198:571–5.
doi:10.1086/590210
127. Brady RA, O’May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolu-
tion of Staphylococcus aureus biofilm infection using vaccination and antibiotic
treatment. Infect Immun (2011) 79:1797–803. doi:10.1128/IAI.00451-10
128. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al.
Development of a multicomponent Staphylococcus aureus vaccine designed to
counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012)
8:1585–94. doi:10.4161/hv.21872
129. Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB. DNA vac-
cines for targeting bacterial infections. Expert Rev Vaccines (2010) 9:747–63.
doi:10.1586/erv.10.57
130. Levitz SM, Golenbock DT. Beyond empiricism: informing vaccine develop-
ment through innate immunity research. Cell (2012) 148:1284–92. doi:10.
1016/j.cell.2012.02.012
131. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bac-
terial persisters by aminoglycosides. Nature (2011) 473:216–20. doi:10.1038/
nature10069
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 31 October 2013; accepted: 22 January 2014; published online: 05 February
2014.
Citation: Scherr TD, Heim CE, Morrison JM and Kielian T (2014) Hiding in plain
sight: interplay between staphylococcal biofilms and host immunity. Front. Immunol.
5:37. doi: 10.3389/fimmu.2014.00037
This article was submitted to Microbial Immunology, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Scherr , Heim, Morrison and Kielian. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 37 | 7
